MEA Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
 

Market Segmentation: 
Middle East and Africa Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary),  Treatment (Surgery, Radiotherapy, Medications),  Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Egypt, Israel, UAE, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
 

Some of the major factors contributing to the growth of the glioblastoma multiforme treatment market are:

• Increasing prevalence of the disease
 

• High incidence in emerging markets.

Market Players:

Some of the major players operating in the market are:

• F. Hoffmann-La Roche AG 
• Amgen Inc. 
• Merck & Co., Inc. 
• Pfizer Inc. 
• Varian Medical Systems, Inc.  (A subsidiary of Siemens Healthcare) 
• ZEISS International 
• Amneal Pharmaceuticals LLC 
• Elekta 
• Sun Pharmaceutical Industries Ltd 
• Teva Pharmaceutical Industries Ltd. 
• Eckert & Ziegler 
• Accord Healthcare 
• Angiochem 
• ANI Pharmaceuticals, Inc. 
• Arbor Pharmaceuticals, LLC.  (A Subsidiary of Azurity Pharmaceuticals, Inc.) 
• AstraZeneca 
• Cantex Pharmaceuticals, Inc. 
• CELON LABS 
• Diffusion Pharmaceuticals Inc. 
• EnGeneIC 
• ERC.SA. 
• Genenta science 
• Jazz Pharmaceuticals, Inc.
• Loxo Oncology (A Subsidiary of Eli Lilly) 
• Novartis AG 
• VBL THERAPEUTICS
• Viatris Inc. 
• Zydus Pharmaceuticals, Inc.,